Viking Therapeutics (VKTX) Other Accumulated Expenses (2014 - 2026)

Viking Therapeutics has disclosed Other Accumulated Expenses across 13 years of filings, most recently posting $39.1 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $39.1 million, up 244.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.1 million (up 244.17% YoY), and the FY2025 annual result was $23.3 million, up 36.05% from the prior year.
• Other Accumulated Expenses came in at $39.1 million for Q1 2026 at Viking Therapeutics, up from $23.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $39.1 million in Q1 2026 to a low of $7.4 million in Q3 2023.
• The 5-year median for Other Accumulated Expenses is $13.1 million (2022), against an average of $16.6 million.
• Across the five-year window, Other Accumulated Expenses slumped 58.22% in 2025 and jumped 244.17% in 2026, its largest moves.
• Viking Therapeutics' Other Accumulated Expenses stood at $13.1 million in 2022, then slipped by 13.84% to $11.3 million in 2023, then jumped by 51.44% to $17.1 million in 2024, then jumped by 36.05% to $23.3 million in 2025, then soared by 68.14% to $39.1 million in 2026.
• The last three Other Accumulated Expenses figures came in at $39.1 million (Q1 2026), $23.3 million (Q4 2025), and $21.2 million (Q3 2025), per Business Quant data.